BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: DeVincenzo JP, Aitken J, Harrison L. Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody. J Pediatr. 2003;143:123-126. [PMID: 12915838 DOI: 10.1016/s0022-3476(03)00213-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Mejías A, Chávez-Bueno S, Ríos AM, Aten MF, Raynor B, Peromingo E, Soni P, Olsen KD, Kiener PA, Gómez AM. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob Agents Chemother. 2005;49:4700-4707. [PMID: 16251314 DOI: 10.1128/aac.49.11.4700-4707.2005] [Cited by in Crossref: 74] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
2 Hijano DR, Maron G, Hayden RT. Respiratory Viral Infections in Patients With Cancer or Undergoing Hematopoietic Cell Transplant. Front Microbiol 2018;9:3097. [PMID: 30619176 DOI: 10.3389/fmicb.2018.03097] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
3 Kuypers J, Wright N, Morrow R. Evaluation of quantitative and type-specific real-time RT-PCR assays for detection of respiratory syncytial virus in respiratory specimens from children. J Clin Virol 2004;31:123-9. [PMID: 15364268 DOI: 10.1016/j.jcv.2004.03.018] [Cited by in Crossref: 104] [Cited by in F6Publishing: 104] [Article Influence: 5.8] [Reference Citation Analysis]
4 Lemon K, Nguyen DT, Ludlow M, Rennick LJ, Yüksel S, van Amerongen G, McQuaid S, Rima BK, de Swart RL, Duprex WP. Recombinant subgroup B human respiratory syncytial virus expressing enhanced green fluorescent protein efficiently replicates in primary human cells and is virulent in cotton rats. J Virol 2015;89:2849-56. [PMID: 25540371 DOI: 10.1128/JVI.03587-14] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
5 Castilow EM, Olson MR, Meyerholz DK, Varga SM. Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus. J Virol 2008;82:2196-207. [PMID: 18094193 DOI: 10.1128/JVI.01949-07] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
6 Kim YI, Pareek R, Murphy R, Harrison L, Farrell E, Cook R, DeVincenzo J. The antiviral effects of RSV fusion inhibitor, MDT-637, on clinical isolates, vs its achievable concentrations in the human respiratory tract and comparison to ribavirin. Influenza Other Respir Viruses 2017;11:525-30. [PMID: 28990339 DOI: 10.1111/irv.12503] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
7 Resch B. Burden of respiratory syncytial virus infection in young children. World J Clin Pediatr 2012; 1(3): 8-12 [PMID: 25254161 DOI: 10.5409/wjcp.v1.i3.8] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
8 Resch B. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection. Hum Vaccin Immunother 2017;13:2138-49. [PMID: 28605249 DOI: 10.1080/21645515.2017.1337614] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 11.6] [Reference Citation Analysis]
9 Rijsbergen LC, Lamers MM, Comvalius AD, Koutstaal RW, Schipper D, Duprex WP, Haagmans BL, de Vries RD, de Swart RL. Human Respiratory Syncytial Virus Subgroup A and B Infections in Nasal, Bronchial, Small-Airway, and Organoid-Derived Respiratory Cultures. mSphere 2021;6:e00237-21. [PMID: 33980679 DOI: 10.1128/mSphere.00237-21] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]